Clinical Trial: Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma

Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional

Official Title: Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma

Brief Summary: The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with cholangiocarcinoma.

Detailed Summary: The primary objective is to evaluate whether RFA followed by CIK transfusion can prolong survival of patients with cholangiocarcinoma.
Sponsor: The First People's Hospital of Changzhou

Current Primary Outcome: Recurrence-free survival [ Time Frame: 1 year ]

Recurrence-free survival (RFS) was defined as the time from the date of RFA to the date of recurrence or the date of the last follow-up.


Original Primary Outcome: Same as current

Current Secondary Outcome: Adverse events [ Time Frame: 4 weeks ]

Adverse events related to RFA and CIK treatments.


Original Secondary Outcome: Same as current

Information By: The First People's Hospital of Changzhou

Dates:
Date Received: June 24, 2015
Date Started: July 2012
Date Completion: July 2033
Last Updated: February 21, 2016
Last Verified: February 2016